Summary & Overview
HCPCS Level II Q5102: Infliximab Biosimilar Injection, 10 mg
HCPCS Level II code Q5102 identifies a 10 mg dose of an infliximab biosimilar administered as an injectable biologic. Infliximab biosimilars are used across multiple immune-mediated conditions and represent a cost-sensitive segment of biologic therapy nationally. Accurate coding for biosimilar infliximab supports claims processing, payer policy alignment, and monitoring of biosimilar uptake.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of billing and clinical context for HCPCS Level II code Q5102, common sites of service, and what to expect in payer coverage policies. The publication outlines benchmarks and policy updates relevant to biosimilar infliximab utilization, administrative coding considerations for dose-based reporting, and the clinical settings where this injection is typically billed.
This summary equips billing managers, revenue cycle leaders, and clinical administrators with a concise reference to the code’s clinical purpose, payer landscape, and the practical information needed for claims and policy review. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code Q5102 represents an injection formulation of infliximab biosimilar, 10 mg. This entry-level code is used to report administration of the biosimilar infliximab product by dose.
Service type: Therapeutic biologic injection
Typical site of service: Outpatient infusion center, hospital outpatient department, or physician office infusion suite
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving Q5102 is an adult with a chronic immune-mediated inflammatory disease such as rheumatoid arthritis, Crohn disease, ulcerative colitis, ankylosing spondylitis, or psoriasis who requires intravenous biologic therapy and is being treated with an infliximab biosimilar dosed in 10 mg increments. The clinical workflow frequently occurs in an outpatient infusion center, hospital outpatient department, or physician office infusion suite staffed by an infusion nurse and supervising physician or advanced practice provider. The patient arrives for a pre-scheduled infusion visit, is screened for recent infections and vital sign stability, and undergoes venous access placement. The pharmacy prepares the infliximab biosimilar dose per weight-based or fixed dosing protocol; the medication is administered intravenously over the recommended infusion time with standard monitoring for infusion reactions. Post-infusion observation is performed, nursing documents medication lot numbers, dose, route, and patient response, and the supervising clinician documents indication, prior biologic therapy, and plan for future dosing intervals. Billing is submitted using HCPCS Level II code Q5102 to represent the administered infliximab biosimilar in 10 mg units, alongside appropriate infusion administration CPT codes and diagnosis codes supporting medical necessity.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|